Effect of Nucleos(t)ide analogues(NAs) therapy on the postoperative survival in patients with hepatitis B virus related hepatocellular carcinoma-a meta analysis

Abstract

Abstract: Objective To investigate the effect of Nucleos(t)ide analogues (NAs) on postoperative survival and prognosis of patients with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). Methods PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, CBM, Wan fang, and Wei pu databases were used for searching, and the deadline was December 2021. Two reviewers screened the literatures independently according to the inclusion and exclusion criteria, then extracted and assessed the data. The meta-analysis was conducted through Stata16. Results A total of 25 studies including 6 randomized controlled trial (RCT) studies and 20 cohort studies were included. Among them, there was a two-stage longitudinal clinical study, which including both a RCT and a cohort study. Our meta-analysis showed that the overall survival (OS) and recurrence free survival (RFS) of the patients in the experimental treated by NAs and hepatic resection, were superior to the patients in control group treated by hepatic resection at the 1st, 3rd, 5th year. Conclusion Compared with the control group, the patients with HBV-HCC who were treated by NAs and hepatic resection could achieve a better OS and RFS.

Key words: Hepatitis B virus, Hepatocellular carcinoma, Hepatic resection, Nucleotide/Nucleoside analogs, Overall survival, Recurrence free survival, Meta analysis

LIU Yun-xiao, FU Yan, NIU Li-na, DOU Jing , WANG Xiao-zhong. Effect of Nucleos(t)ide analogues(NAs) therapy on the postoperative survival in patients with hepatitis B virus related hepatocellular carcinoma-a meta analysis[J]. Chinese Hepatolgy, 2023, 28(2): 181-188.

References

[1] Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol,2013,31(29):3647-3655.
[2] Wang C, Cao Y, Yang C, et al. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol,2021,18(10):690-704.
[3] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers,2021,7(1):6.
[4] Shi J F, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050?. Int J Cancer,2021,148(5):1051-1065.
[5] Lin S Y, Zhang A, Lian J, et al. Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma. Cells,2021,10(6):1294.
[6] 中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版).临床肝胆病杂志,2021,37(10):2292-2302.
[7] Zhou Y, Zhang Z, Zhao Y, et al. Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis. World J Surg,2014,38(9):2395-2402.
[8] 张其顺. 拉米夫定在肝癌合并乙型肝炎术后治疗中的应. 肿瘤防治究,2010,37(9):1064-1066.
[9] Chan ACY, Chok KSH, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg,2011,146(6):675-681.
[10] Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol,2012,38(8):683-691.
[11] 柯阳, 钟鉴宏, 游雪梅, 等. 抗病毒治疗对乙型肝炎病毒相关性肝细胞癌患者根治性术后的影响.中国肿瘤临床,2013,40(19):1184-1188.
[12] 张磊, 侍作亮, 卞建民. 乙肝相关性肝癌根治性术后抗病毒治疗对于患者预后的影响.海南医学院学报,2014,20(11):1536-1537.
[13] 丁晨, 潘凡, 胡还章, 等. HBVDNA高载量的肝细胞癌患者肝癌根治术后抗病毒治疗疗效观察.临床肝胆病杂志,2014,30(7):656-659.
[14] 李敏基, 蒋忠胜, 韦静彬, 等. 抗乙肝病毒治疗与原发性肝癌术后生存关系研究分析.肝胆外科杂志,2015(3):209-210.
[15] 陈勇. 抗病毒治疗在肝炎相关肝癌术后复发中的作用.中国生物药物杂志,2015,35(1):97-99.
[16] 俞文渊, 王强, 严冬华, 等. 规范化抗乙肝病毒治疗在肝癌肝切除术后癌症复发的回顾性研究.肝胆外科杂志,2015,23(2):126-129.
[17] Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg,2015,261(1):56-66.
[18] 田云鸿, 杨红春, 彭勇, 等. 乙肝肝癌切除术抗病毒治疗疗效观察.中国普外基础与临床杂志,2015,22(10):1187-1191.
[19] 王伯庆, 薛峰, 佟庆, 等. 抗病毒治疗对乙型肝炎相关肝癌根治术后复发和生存的影响.实用肝脏病杂志,2015,18(2):132-135.
[20] 姚红兵, 文明波, 华赟鹏, 等. 核苷(酸)类似物抗病毒治疗对乙型肝炎病毒相关性肝癌术后临床转归的影响.实用医学杂志,2016,32(15):2468-2470.
[21] Liu XF, Zhang T, Tang K, et al. Study of preoperative antiviral treatment of patients with HCC negative for HBV-DNA. Anti cancer Res,2017,37(8):4701-4706.
[22] Wei Q, Tian H, Luo H, et al. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Asian J Surg,2017,40(6):453-462.
[23] 杨俊杰, 鄢业鸿. 抗病毒治疗对乙肝相关性肝细胞癌术后预后的影响.广东医学,2018,39(4):587-592+596.
[24] 唐维, 黄广优, 陈坚贤, 等. 根治性肝切除术后抗病毒治疗对HBV相关性肝细胞癌患者预后的影响,广西医学,2018,40(3):279-283.
[25] Huang G, Li P, Lau W Y, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg,2018,268(6):943-954.
[26] Zhao J, Wang J, Chai S, et al. Elevated lactate impairs the efficacy of antiviral treatment on post-hepatectomy survival for advanced stage hepatitis B virus-related hepatocellular carcinoma. Clin Res Hepatol Gastroenterol,2019,43(1):67-76.
[27] Xu M, Zhou Z, Xu R, et al. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol,2019,17(1):45.
[28] Wang Z, Tao Q, Wang Z, et al. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm-A retrospective cohort study. Am J Surg,2020,219(4):717-725.
[29] Li C, Li Z C, Ma L, et al. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol,2020,14(8):749-756.
[30] Kong J, Liang X, Zhang J, et al. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis. Dig Dis Sci,2021:1-8.
[31] Fu J, Ding Z, Chen Q, et al. Distinct Impacts of Pre-Operative Antiviral Treatment on Post-Operative Outcomes of HBV-related Hepatocellular Carcinoma: A Landmark Analysis. J Cancer,2021,12(1):170-180.
[32] Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis, 2020,7(3):291-298.
[33] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int,2017,11(4):317-370.
[34] Xing H, Zhang W G, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB(Oxford),2020,22(5):677-689.
[35] Papatheodoridi M, Tampaki M, Lok A S, et al. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology,2022,75(5):1257-1274.
[36] Rehman M. A Review on the Management of Chronic Hepatitis B and C Infection. Global Immunological & Infectious Diseases Review (GIIDR),2017(II-I):49-62.
[37] Zhang X, Li C, Wen T, et al. The different effects of nucleotide and nucleoside analogues on the prognosis of HBV-related HCC after curative resection. J Gastrointest Surg,2021,25(6):1419-1429.
[38] Shen JY, Qi WL, Dai JL, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. Chin Med J(Engl),2021,135(3):301-308.
[39] Zhang M, Wang D, Liu H, et al. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer,2018,13:19.